Regenerative Medical Technology Group (RMTG) (OTCID: RMTG) has announced that its Cellgenic division has launched a natural killer (NK) cell product line for permitted markets outside the U.S., with an initial commercial focus on Latin America and Southeast Asia.
According to RMTG, international demand for advanced cellular and immunology-related technology has continued to grow and the NK cell launch reflects Cellgenic’s broader strategy of expanding its product portfolio to meet physician and customer demand in permitted markets.
In a statement, David Christensen, CEO and president of RMTG, commented, “Natural killer cell technology represents one of the more active areas of interest in cellular science today. Adding an NK cell product line lets Cellgenic meet physician demand we are already seeing internationally, and it is a natural extension of the cellular-technology platform we have built.”
